Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

348528

registered interest
date	04/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mesothelioma: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the adequacy of the finance for research into mesothelioma; and if he will make a statement.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	1216
answer	answer is ministerial correction date of answer 09/06/2015 answer text <p>The Department’s National Institute for Health Research (NIHR) has invited researchers to apply for mesothelioma research funding, in particular to address the research questions identified through the Mesothelioma Priority Setting Partnership and published in December 2014. Eight NIHR programmes are participating in this themed call. Four funding applications for research specifically in mesothelioma are currently under review. The call under the Health Technology Assessment programme closes on 3 September 2015.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/06/2015 13:00:37 answering member 4020 label Biography information for George Freeman
tabling member	253 label Biography information for Mr Laurence Robertson

348377

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Tobacco: Packaging
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what preparations his Department is making for the commencement of the Standardised Packaging of Tobacco Products Regulations 2015 on 20 May 2016.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	1058
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Guidance will be made available to local authority trading standards officers, or in the case of Northern Ireland, environmental health officers. It will be developed with the relevant bodies responsible and made publically available before the Standardised Packaging of Tobacco Products Regulations 2015 come into force.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/06/2015 15:28:25 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

348390

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Motor Vehicles: Smoking
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what preparations his Department is making for the commencement of the Smoke-free (Private Vehicles) Regulations 2015 on 1 October 2015.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	1077
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>There will be a communications campaign to raise awareness of the Smoke-free (Private Vehicles) Regulations 2015 in advance of them coming into force on 1 October. Guidance and training materials are currently being developed and will be available for the police and local authority enforcement officers. Information will be available for local authorities so that they can work locally to help build compliance and raise awareness.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/06/2015 14:30:03 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

348391

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cervical Cancer: Health Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the contribution of the Parliamentary Under-Secretary of State for Health of 1 May 2014, Official Report, column 1052, on cervical cancer screening, whether Ministers in his Department hosted a special day in Parliament on the take-up of cervical cancer screening and HPV vaccinations.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	1100
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>As I said in the debate on 1 May 2014, Official Report, column 1052, if hon. and Rt. hon. Members indicated that they would want to initiate a Parliamentary event on cervical screening and the Human Papilloma Virus (HPV) vaccination, I would be happy to support it. Although, to date, I have received no specific representations from any hon. or Rt. hon. Members, I remain happy to support such an event.</p><p> </p><p> </p><p> </p><p>In April 2012 the UK National Screening Committee (UKNSC) gave its support for a pilot to assess the value of using HPV testing as primary screening (HPV TaPS) for cervical disease, rather than the currently used cytology test. The pilot is establishing the feasibility of using HPV testing as the primary screen for cervical disease in order to achieve better outcomes for women, while minimising over-treatment and anxiety, and whether it is practical to roll out nationally. The UK NSC will open a public consultation shortly on whether HPV TaPS for cervical disease should replace the currently used cytology test.</p><p> </p><p> </p><p> </p><p>Public Health England (PHE) continues to work with NHS England via the Public Health Section 7A agreement to develop a system of performance improvement through the use of performance floors, and strengthened governance for screening. The aims of the performance floors are:</p><p> </p><p><br> - Improving performance and equity of service over time by reducing the range of variation at a local level.</p><p> </p><p>- Enabling easy identification of poor performance and the setting of objectives and plans for local action, to reduce variation and improve performance.</p><p> </p><p> </p><p> </p><p>PHE will look at research provided by the STRATEGIC study (Strategies to increase cervical screening uptake at first invitation) to identify methods to help increase uptake among women. The STRATEGIC study will be publishing findings in May 2016, more details of this can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nets.nihr.ac.uk/projects/hta/0916401" target="_blank">http://www.nets.nihr.ac.uk/projects/hta/0916401</a></p><p> </p><p> </p><p> </p><p>The Responsibility Deal Health at Work Network has worked with employers to develop the Staff Health Checks pledge, which encourages eligible employees to participate in NHS Health, and other NHS screening programmes. 160 employers have signed up to this pledge.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 1101 question first answered 08/06/2015 15:54:52 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

348392

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cervical Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the contribution of the Parliamentary Under-Secretary of State for Health of 1 May 2014, Official Report, column 1052, on cervical cancer screening, what steps his Department has taken to modernise the NHS cervical cancer screening programme; what progress has been made by Public Health England on addressing low coverage of cervical cancer screening in certain areas and working on local action plans to improve such coverage; and what work his Department has carried out with employers to encourage them to make it clear to young women that they will facilitate them taking time off for cervical cancer screening.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	1101
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>As I said in the debate on 1 May 2014, Official Report, column 1052, if hon. and Rt. hon. Members indicated that they would want to initiate a Parliamentary event on cervical screening and the Human Papilloma Virus (HPV) vaccination, I would be happy to support it. Although, to date, I have received no specific representations from any hon. or Rt. hon. Members, I remain happy to support such an event.</p><p> </p><p> </p><p> </p><p>In April 2012 the UK National Screening Committee (UKNSC) gave its support for a pilot to assess the value of using HPV testing as primary screening (HPV TaPS) for cervical disease, rather than the currently used cytology test. The pilot is establishing the feasibility of using HPV testing as the primary screen for cervical disease in order to achieve better outcomes for women, while minimising over-treatment and anxiety, and whether it is practical to roll out nationally. The UK NSC will open a public consultation shortly on whether HPV TaPS for cervical disease should replace the currently used cytology test.</p><p> </p><p> </p><p> </p><p>Public Health England (PHE) continues to work with NHS England via the Public Health Section 7A agreement to develop a system of performance improvement through the use of performance floors, and strengthened governance for screening. The aims of the performance floors are:</p><p> </p><p><br> - Improving performance and equity of service over time by reducing the range of variation at a local level.</p><p> </p><p>- Enabling easy identification of poor performance and the setting of objectives and plans for local action, to reduce variation and improve performance.</p><p> </p><p> </p><p> </p><p>PHE will look at research provided by the STRATEGIC study (Strategies to increase cervical screening uptake at first invitation) to identify methods to help increase uptake among women. The STRATEGIC study will be publishing findings in May 2016, more details of this can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nets.nihr.ac.uk/projects/hta/0916401" target="_blank">http://www.nets.nihr.ac.uk/projects/hta/0916401</a></p><p> </p><p> </p><p> </p><p>The Responsibility Deal Health at Work Network has worked with employers to develop the Staff Health Checks pledge, which encourages eligible employees to participate in NHS Health, and other NHS screening programmes. 160 employers have signed up to this pledge.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 1100 question first answered 08/06/2015 15:54:53 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

348396

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what proportion of cancer patients received (a) intensity modulated and (b) stereotactic radiotherapy in the latest month for which figures are available.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	952
answer	answer is ministerial correction date of answer 09/06/2015 answer text <p>NHS England monitors the progress in achieving the following standard:</p><p> </p><p> </p><p> </p><p>- A minimum 24% of patients requiring radical radiotherapy have access to inverse planned Intensity Modulated Radiotherapy (IMRT).</p><p> </p><p> </p><p> </p><p>NHS England monitors this standard as a three month rolling average. The latest data shows that 6,397 patients received IMRT during the period from December 2014 to February 2015, a proportion of 37% of patients requiring radical radiotherapy.</p><p> </p><p> </p><p> </p><p>NHS England does not hold data centrally relating to the proportion of cancer patients receiving stereotactic radiotherapy.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 09/06/2015 14:33:38 answering member 3918 label Biography information for Jane Ellison
tabling member	1506 label Biography information for Andrew Gwynne

348397

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa: Health Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to raise awareness of hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	962
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 963 964 965 question first answered 08/06/2015 10:53:58 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348398

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate his Department has made of the number of people with hidradenitis suppurativa in the UK; how much his Department has spent on research into hidradenitis suppurativa in the last four years; and what guidance his Department gives on support to be given through the NHS for people with hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	963
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 964 965 question first answered 08/06/2015 10:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348399

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the effectiveness of the care pathways for patients with hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	964
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 963 965 question first answered 08/06/2015 10:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348400

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department has taken to provide information to surgeons, dermatologists and general practitioners about hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	965
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 963 964 question first answered 08/06/2015 10:54:01 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper